Figure 9. ERRFI1 regulates organoid growth, therapy response and AKT activation depending on EGFR level.

• A
  Organoid lysates from six human breast cancer PDX tumors were blotted with EGFR antibody. Quantification of EGFR protein relative to the GAPDH was determined. Error bars represent the SEM of three independent experiments.
• B, C
  EGFR‐high BJ06 and BJ16 organoids transfected with siERRFI1 were treated with vehicle (Veh) or 50 nM of gemcitabine (Gem) alone or in combination with either 10 μM gefitinib (G) or 10 μM TCN (T). Organoid growth was monitored every 3 days. Knockdown efficiency is shown in (F). Error bars represent the SEM of three independent experiments. **P < 0.01. Statistical analyses were performed with Student's t‐test.
• D, E
  EGFR‐low BJ43 and BJ44 organoids transfected with ERRFI1 plasmid were treated as above. Organoid growth was monitored every 3 days. Overexpression efficiency is shown in (G). Error bars represent the SEM of three independent experiments. **P < 0.01. Statistical analyses were performed with Student's t‐test.
• F, G
  BJ06 and BJ44 organoids were treated with vehicle or 50 nM of Gem alone or in combination with either 10 μM of G or 10 μM of T for 72 h. Organoid lysates were blotted with the indicated antibodies.

Source data are available online for this figure.